Literature DB >> 10402236

The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines.

E M Gilhooly1, D P Rose.   

Abstract

Cyclooxygenase (COX) is rate-limiting for arachidonic acid metabolism to the prostanoid family of eicosanoids. Some human breast cancers, notably those which are estrogen receptor (ER)-negative with high metastatic potential, produce high levels of prostaglandin E2 (PGE2). In some cell types, expression of the inducible COX-2 isoform occurred in association with a ras gene mutation. We determined COX-1 and COX-2 expression, and the corresponding PGE2 secretions, in 4 ER-negative human breast cancer cell lines, the MCF10A breast epithelial cell line, and the same non-cancerous line transfected with a mutated ras gene. The highly invasive MDA-MB-231 and Hs578T cancer cell lines, which possess a mutated Ki-ras and H-ras, respectively, expressed constitutive and inducible COX-2, and produced high PGE2 levels; the less invasive MDA-MB-435 and SK-BR-3 lines, without a mutated ras, possessed only low levels of COX-2, and secreted correspondingly low PGE2 levels. Similarly, the ras transfectant, but not parental MCF10A cells, expressed inducible COX-2. Chemosuppression with a selective COX-2 inhibitor may be effective only in that minority of breast cancers which have a mutated ras gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402236

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

2.  The CRAL/TRIO and GOLD domain protein TAP-1 regulates RAF-1 activation.

Authors:  Kenneth G Johnson; Kerry Kornfeld
Journal:  Dev Biol       Date:  2010-03-15       Impact factor: 3.582

3.  COX-1 and -2 expressions in sex-related organs of neonatally estrogen-treated rats and in activated and nonactivated macrophage RAW264.7 cells with phytoestrogen.

Authors:  Cheng Luo; Ying Peng; Risto Santti; Ming Liang He; Marie C Lin
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output.

Authors:  M E Miller; A C Holloway; W G Foster
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.

Authors:  Vipin Yadav; Mitchell F Denning
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

6.  Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.

Authors:  Li Ma; Yong-Le Xie; Yi Yu; Qiu-Ning Zhang
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

7.  Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

Authors:  C Costa; R Soares; J S Reis-Filho; D Leitão; I Amendoeira; F C Schmitt
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

8.  Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.

Authors:  Fatemeh Kalalinia; Fatemeh Elahian; Javad Behravan
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-27       Impact factor: 4.553

9.  Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.

Authors:  Olfat Ali Hammam; Ahmed A Aziz; Mamdouh S Roshdy; Ahmed M Abdel Hadi
Journal:  Medscape J Med       Date:  2008-03-11

10.  Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion.

Authors:  Michelle A Booden; Lynn B Eckert; Channing J Der; JoAnn Trejo
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.